Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999408 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning
A NA study of Alopecia and Hair Thinning, sponsored by Recens Medical.
- Active
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06999408 is a NA study of Alopecia and Hair Thinning that is active but no longer recruiting, run by Recens Medical. The registered enrollment target is 15 participants, below the 124-participant average among 13 other Alopecia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06999408, a NA study of Alopecia and Hair Thinning, is active but no longer recruiting, sponsored by Recens Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is testing a new approach to help improve hair thinning using a combination of cosmetic treatments. The purpose of the study is to learn whether applying exosomes to the scalp, along with microneedling and a precision cooling device called TargetCool™. This study aims to determine whether this combination approach offers synergistic benefits for individuals with hair thinning. Exosomes are tiny particles that come from stem cells and contain growth factors and other nutrients. They are being studied for their potential to help regenerate skin and hair. TargetCool™ is an FDA-cleared device that uses precision cooling to reduce inflammation and improve comfort. Microneedling is a common, minimally invasive procedure that uses small needles to stimulate the skin and help absorb topical products more effectively. The study will include healthy men (ages 18 to 70) and women (ages approximately 45 to 70) who are not of childbearing potential. A total of 9 to 15 participants will be randomly placed into one of three groups: Group 1: Exosomes with TargetCool™ Group 2: Microneedling followed by exosomes and TargetCool™ Group 3: Microneedling followed by exosomes only Participants will receive four treatments over 9 weeks. Each visit may include microneedling, TargetCool™ treatment, and exosome application depending on group assignment. A small tattoo will be placed on the scalp to help capture consistent photographs, and a special imaging system (Canfield HairMetrix®) will be used to measure hair changes. Participants will return for follow-up visits at 3 and 6 months after the final treatment. The results will help determine whether this combination of cosmetic treatments is safe and beneficial for people experiencing hair thinning.
Conditions Studied
Interventions
- DEVICE Scalp tattoo
- DEVICE Canfield HairMetrix®
- DEVICE TargetCool
- DEVICE Microneedle-facilitated lidocaine application
Study Locations (1)
New York
- Marc Avram MD - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2026-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06999408
The ClinicalTrials.gov registry entry for NCT06999408 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 124-participant average among 13 other Alopecia trials with a reported enrollment target (88% lower). The listed sponsor is Recens Medical, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alopecia appearing as the primary indexed condition, and to 4 interventions - of which Scalp tattoo is the first listed.
NCT06999408 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06999408 about?
NCT06999408 is a clinical study titled "Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning". This clinical trial is testing a new approach to help improve hair thinning using a combination of cosmetic treatments. The purpose of the study is to learn whether applying exosomes to the scalp, along with microneedling and a precision cooling device called TargetCool™. This study aims to determin...
What is the current status of trial NCT06999408?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-09-16. Estimated completion is 2026-05.
What conditions does trial NCT06999408 study?
This clinical trial studies the following conditions: Alopecia, Hair Thinning, Hair Diseases.
What interventions are being tested in trial NCT06999408?
The interventions under investigation include: Scalp tattoo (DEVICE), Canfield HairMetrix® (DEVICE), TargetCool (DEVICE), Microneedle-facilitated lidocaine application (DEVICE).
Who is sponsoring clinical trial NCT06999408?
This trial is sponsored by Recens Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06999408 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
RECRUITING · NA
-
Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors
RECRUITING · NA
-
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
RECRUITING · NA
-
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
RECRUITING · NA
-
Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region
RECRUITING · NA
-
Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.